Interesting predictive test15 Jan 2024 12:01
The company has a strong value proposition for the NHS and hence commissioner approval with budgets absorbing that spend unless the baseline for Integrated Commisioning Boards can be adjusted for the 2425 financial year to allow for the adoption of this innovative test. Buys are 3x Sell orders yet the bid price is almost 5% down! Perhaps a large buyer is being accomodated by market makers at a favourable entry level. DYOR. I used to commission services within the NHS, IMO- buy and hold . There is bound to be volatility in the price, after all this is AIM, where fortunes can be made and lost too.